Skip to main content

Cervical Tumors from Ugandan Patients, Immunoprofiler Consortium, and Clinical Trials Stemming from CTD^2 Network: August OCG e-Newsletter

, by OCG Staff

Topics from the Office of Cancer Genomics's August 2020 e-Newsletter.

The Summer 2020 edition of the Office of Cancer Genomics (OCG) e-Newsletter features a genomic study of cervical cancers in Ugandan patients, the UCSF Immunoprofiler Consortium, updates on HCMI’s next-generation cancer models, clinical trials informed by the CTD2 Network’s research, and a perspective article by Julyann Pérez-Mayoral, Ph.D., the new HCMI program manager. OCG is a member office of the Center for Cancer Genomics.

Analysis of Ugandan Cervical Carcinomas Identifies Human Papillomavirus (HPV) Clade-Specific Epigenome and Transcriptome Landscapes

Nick Griner, Ph.D. and Cindy Kyi, Ph.D.

A recent large-scale genomic study conducted in Ugandan cervical cancer patients describes the molecular landscapes of an understudied population and provides insights into how human papillomavirus (HPV) clades, HIV status, and genetic background may affect the formation and progress of cervical cancer. The study was a part of the HIV+ Tumor Molecular Characterization Project (HTMCP).

Immunoprofiler Consortium at the University of California, San Francisco (UCSF)

Vincent Chan, Ph.D., Alexis Combes, Ph.D., Elizabeth Edmiston, Ph.D. and Matthew Krummel, Ph.D.

The UCSF Immunoprofiler Consortium is a unique collaboration between academia and industry that aims to understand the nature of immune responses across various cancers and identify biomarkers to discover targets for new therapeutic interventions.

Next-Generation Cancer Models Available as a Community Resource

Eva Tonsing-Carter, Ph.D. and Cindy Kyi, Ph.D.

The Human Cancer Models Initiative (HCMI) is an international consortium generating patient-derived next-generation cancer models and case-associated data as a community resource. The article provides updates on the cancer types, model types, and tissue types of models available and clinical and genomic data corresponding to models available at NCI’s Genomic Data Commons.

Bridging the Gap: CTD2 Network Research Findings Undergoing Testing in Clinical Trials

Subhashini Jagu, Ph.D.

The CTD2 Network aims to understand cancer metastasis, tumor heterogeneity, and drug resistance, and importantly, develop optimal drug combinations. Here is a summary of clinical trials testing small molecule inhibitors and immunological agents informed by CTD2 research.

Contributing to Precision Oncology by Expanding Basic Research Capacities Using Next-generation Cancer Models

Julyann Pérez-Mayoral, Ph.D.

Dr. Julyann Pérez-Mayoral, a new program manager for the Human Cancer Models Initiative (HCMI) shares her cancer research experience in Puerto Rico, where she used genetics and genomics to reduce cancer health disparities in an underserved population.

< Older Post

Continuing Our Work in the Time of Two Pandemics

Newer Post >

Visualizing Single-Cell RNA-Seq Data with t-SNE: Researcher Interview with Dmitry Kobak and Philipp Berens

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Cervical Tumors from Ugandan Patients, Immunoprofiler Consortium, and Clinical Trials Stemming from CTD^2 Network: August OCG e-Newsletter was originally published by the National Cancer Institute.”

Featured Posts

Archive